Stevanato Group S.p.A. (STVN) Stock Price & How to Invest

Stevanato Group has been making pharmaceutical glass in Piombino Dese, near Padua in northern Italy, since 1949, and sells its containers under the Ompi brand. The business runs in two segments. Biopharmaceutical and Diagnostic Solutions covers vials, syringes, cartridges, EZ-fill ready-to-use containers and the Alina pen injector platform, and produced ~EUR 266.2 million of the ~EUR 302.0 million total in the second quarter of 2026. Engineering builds the assembly, visual inspection and glass converting machinery that drug makers and other packaging firms use on their own lines, and contributed the remaining ~EUR 35.8 million. The company listed ordinary shares on the New York Stock Exchange in July 2021, but it remains an Italian issuer that reports in euros and files as a foreign private issuer, and the founding family retains roughly four fifths of the shares through Stevanato Holding S.r.l., with Italian loyalty-share rules adding extra votes on top of that.

The investment picture turns on mix. Ordinary bulk glass is a commodity with thin margins and a customer base that periodically works down inventory, which is exactly what caused the 2024 destocking shock. What Stevanato calls high-value solutions, meaning sterilized ready-to-use containers and integrated delivery devices, carries far better economics and reached ~45% of second-quarter revenue at ~EUR 135.9 million, growing ~16% year over year while the total grew ~8%. Management guides that share to ~47% to ~48% for the full year. Second-quarter adjusted EBITDA margin came in at ~26.0%, up ~280 basis points, which is the mix shift showing up in the numbers. Against that, the company is spending heavily to build the capacity the shift requires, at Fishers in Indiana and Latina in Italy, so first-half capital expenditure of ~EUR 119.6 million pushed free cash flow to ~negative EUR 26.6 million and net debt to ~EUR 360.3 million. Buyers of the shares are funding a multi-year build-out before the returns on it arrive.

Customer destocking has hit this company before and can again: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and several plaintiff firms opened investigations afterward (as of August 2026 no securities class action complaint with a case number appears to have been filed, so those remain investigations rather than litigation). Capital intensity is the near-term drag, with first-half 2026 capital expenditure of ~EUR 119.6 million, free cash flow of ~negative EUR 26.6 million and net debt of ~EUR 360.3 million, and full-year free cash flow guided only to a range of breakeven to ~EUR 20 million. Concentration cuts both ways, since ~22% to ~23% of revenue tied to GLP-1 therapies is a tailwind while the class is expanding and a single point of failure if pricing, supply or dosing formats change. Governance leaves outside holders with limited influence, because family control through Stevanato Holding S.r.l. plus enhanced voting rights means minority shareholders cannot force a change of direction. Finally, the reporting currency is the euro while the quote is in dollars, so a US holder absorbs the exchange rate on top of the operating result, and at roughly ~40 times trailing and ~30 times forward earnings the price already assumes the mix shift and the new plants deliver.

11 analysts publish price targets on STVN, averaging $24.83 against a $22.84 price as of August 2026, or +8.7%. The published targets run from $20.00 to $32.00, a moderate spread, and the ratings split 9 buy, 3 hold, 0 sell. Over the last six months there have been 0 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full STVN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Stevanato Group S.p.A.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The high-value solutions mix shift. Ready-to-use sterilized containers and integrated delivery systems reached ~45% of second-quarter 2026 revenue at ~EUR 135.9 million, growing ~16% against ~8% for the group. The most optimistic published target, $32.00, assumes this works close to its best case.

The case against. Customer destocking has hit this company before and can again: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and several plaintiff firms opened investigations afterward (as of August 2026 no securities class action complaint with a case number appears to have been filed, so those remain investigations rather than litigation). The most pessimistic target, $20.00, is roughly what STVN is worth if this bites instead.

Read the full bull and bear case on STVN, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Stevanato Group S.p.A.'s investor relations page or your broker.

• Revenue (TTM): ~EUR 1.20 billion (about ~$1.40 billion)
• Q2 2026 revenue: ~EUR 302.0 million, up ~8% year over year
• Q2 2026 margins: gross ~28.7%, adjusted EBITDA ~26.0%, adjusted diluted EPS ~EUR 0.14
• FY2026 company guidance: revenue ~EUR 1.260 to ~EUR 1.280 billion, adjusted diluted EPS ~EUR 0.60 to ~EUR 0.62
• Market capitalization: ~$6.2 billion at ~$22.58 per share (NYSE)
• Valuation and balance sheet: ~40x trailing earnings, ~30x forward, net debt ~EUR 360.3 million

Every operating figure above is reported in euros because Stevanato is an Italian issuer, while the share price and market capitalization are quoted in US dollars on the NYSE, so the two sets of numbers move on different currencies and should not be compared directly. A trailing multiple near ~40 times sits well above the growth rate of the overall business at ~8%, which only makes sense if the high-value solutions line keeps compounding in the mid teens and pulls group margins with it. The guided free cash flow range of breakeven to ~EUR 20 million for 2026 is the reminder that the capacity build is still consuming what the operations generate.

Other names that sit close to STVN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get STVN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so STVN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where STVN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Stevanato is a supplier to the injectable drug industry with a genuine mix shift into premium containment and delivery systems underway, carried at a growth multiple while heavy plant construction keeps free cash flow close to zero.

Whether STVN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is STVN a buy or a sell?, and where the stock could go from here in the STVN stock forecast.

For income investors, whether STVN pays a dividend and how the payout looks is covered in does STVN pay a dividend? And to weigh STVN against a peer, read the full side-by-side comparisons: STVN vs BDX and STVN vs HNGE.